463 related articles for article (PubMed ID: 33992189)
21. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
[TBL] [Abstract][Full Text] [Related]
22. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.
Caccamo D; Gorgone G; Currò M; Parisi G; Di Iorio W; Menichetti C; Belcastro V; Parnetti L; Rossi A; Pisani F; Ientile R; Calabresi P
Neuromolecular Med; 2007; 9(3):249-54. PubMed ID: 17914182
[TBL] [Abstract][Full Text] [Related]
23. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
Ozer F; Meral H; Hanoglu L; Aydemir T; Yilsen M; Cetin S; Ozturk O; Seval H; Koldas M
Neurol Res; 2006 Dec; 28(8):853-8. PubMed ID: 17288745
[TBL] [Abstract][Full Text] [Related]
24. The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.
Grofik M; Sivák Š; Nosáľ V; Turčanová Koprušáková M; Michalik J; Čierny D; Tatarková Z; Kurča E
J Neurol Sci; 2018 Sep; 392():28-31. PubMed ID: 30097148
[No Abstract] [Full Text] [Related]
25. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
[TBL] [Abstract][Full Text] [Related]
26. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
[TBL] [Abstract][Full Text] [Related]
27. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
Hu XW; Qin SM; Li D; Hu LF; Liu CF
Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663
[TBL] [Abstract][Full Text] [Related]
28. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
dos Santos EF; Busanello EN; Miglioranza A; Zanatta A; Barchak AG; Vargas CR; Saute J; Rosa C; Carrion MJ; Camargo D; Dalbem A; da Costa JC; de Sousa Miguel SR; de Mello Rieder CR; Wajner M
Metab Brain Dis; 2009 Jun; 24(2):257-69. PubMed ID: 19294496
[TBL] [Abstract][Full Text] [Related]
29. Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson's Disease: A Meta-Analysis.
Kim JH; Jin S; Eo H; Oh MS; Lim Y
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839259
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
31. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
32. Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
Bet L; Bareggi SR; Pacei F; Bondiolotti G; Meola G; Schapira AH
Eur J Neurol; 2008 Mar; 15(3):268-73. PubMed ID: 18290846
[TBL] [Abstract][Full Text] [Related]
33. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Miller JW; Selhub J; Nadeau MR; Thomas CA; Feldman RG; Wolf PA
Neurology; 2003 Apr; 60(7):1125-9. PubMed ID: 12682318
[TBL] [Abstract][Full Text] [Related]
34. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G
Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165
[TBL] [Abstract][Full Text] [Related]
35. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
36. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
38. Homocysteine, vitamin B12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients.
De Vecchi AF; Bamonti-Catena F; Finazzi S; Campolo J; Taioli E; Novembrino C; Colucci P; Accinni R; De Franceschi M; Fasano MA; Maiolo AT
Perit Dial Int; 2000; 20(2):169-73. PubMed ID: 10809239
[TBL] [Abstract][Full Text] [Related]
39. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
40. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]